Efficacy of Combined Abelmoschus manihot and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial

Diabetes Care. 2022 Jul 7;45(7):e113-e115. doi: 10.2337/dc22-0607.
No abstract available

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Letter

MeSH terms

  • Abelmoschus*
  • Albuminuria / drug therapy
  • Biphenyl Compounds
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetic Nephropathies* / drug therapy
  • Double-Blind Method
  • Humans
  • Irbesartan / therapeutic use
  • Tetrazoles
  • Treatment Outcome

Substances

  • Biphenyl Compounds
  • Tetrazoles
  • Irbesartan

Associated data

  • ClinicalTrials.gov/NCT03016832